OncoMatch/Clinical Trials/NCT06528496
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Is NCT06528496 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for high-risk neuroblastoma.
Treatment: DANYELZA · Sargramostim · Cytoxan · Topotecan · Vincristine · Doxorubicin · Ifosfamide · Etoposide · Carboplatin · Irinotecan · Temozolomide — The purpose of this study is to find out whether N10 chemotherapy is a safe and effective treatment for children with high-risk neuroblastoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Other
Cancer type
Neuroblastoma
Biomarker criteria
Required: MYCN amplification
Disease stage
Required: Stage L2
Demographics
Prior therapy
Lab requirements
Blood counts
No severe hematologic dysfunction (toxicity >= grade 3)
Kidney function
No severe renal dysfunction (toxicity >= grade 3)
Liver function
No severe hepatic dysfunction (toxicity >= grade 3)
Cardiac function
No severe cardiac dysfunction (toxicity >= grade 3)
Severe dysfunction of major organs, i.e., renal, cardiac, hepatic, neurologic, pulmonary, hematologic, or gastrointestinal toxicity >= to grade 3. Organ dysfunction due to direct effects of primary tumor or metastatic disease, or due to paraneoplastic syndromes associated with neuroblastoma, will not be considered in exclusion criteria. Similarly, complications of interventions to control above direct effects (e.g., steroid-induced hyperglycemia or hypertension) will also not be considered in exclusion criteria
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06528496 currently recruiting?
Yes, this trial is currently recruiting patients.
Does this trial require MYCN?
Yes, MYCN amplification is a required biomarker for enrollment.
What disease stage is eligible?
Stage L2 is required.
Is there an age limit?
Yes. Patients must be 19 years or younger and at least 1 years old.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages